Organon & Co.

OGN

Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.

Revenue
−1.75%
EPS
+1.64%
Free cash flow
+118.8%
Total debt
−3.10%

Quarter to September 2026, against a year earlier

13.87 0.08 +0.58%
Market cap
$3.6B
P/E
17.3×
Fwd P/E
6.2×
Dividend yield
0.58%
F-score
5/9
ROIC
6.26%
Net debt / EBITDA
5.6×
Dividend safety
45/100

Organon & Co. (OGN) P/E ratio

Alert me on P/E ratio

As of 6 November 2026, Organon & Co. (OGN) trades at a P/E ratio of 17.3×. Over the past ten years it has ranged from 2.8× (May 2025) to 17.4× (September 2026); the current reading is higher than 98% of that period. That is below the Drug Manufacturers General industry median of 26.5× and below the Healthcare sector median of 24.5×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 10.0× 123.60%
FY2024 4.5× 21.71%
FY2023 3.7× (53.07%)
FY2022 7.8× 36.48%
FY2021 5.7× 25.89%
FY2020 4.5× 0.00%
FY2019 4.5× 0.00%
FY2018 4.5× 0.00%
FY2017 4.5× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 17.1× (0.08%)
Jun 2026 17.1× 168.96%
Mar 2026 6.4× (36.01%)
Dec 2025 10.0× 79.96%
23 more quarters

Against its own ten years

Low 2.8× High 17.4×
Ten-year median 5.8×
Current reading's percentile 98

P/E ratio against peers

Company P/E ratio
AMRN Amarin Corporation PLC compare n/m
NVO Novo Nordisk A/S compare 10.1×
BMY Bristol Myers Squibb Company compare 13.7×
GSK GSK PLC Sponsored ADR compare 16.7×
OGN Organon & Co. 17.3×
GRFS Grifols, S.A. compare 18.2×
SNY Sanofi compare 23.3×
PFE Pfizer Inc. compare 41.3×
BIIB Biogen Inc. compare 105×
Drug Manufacturers General industry median 26.5×
Healthcare sector median 24.5×
Market median 17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on OGN